Pannexin-I/P2X 7 Purinergic Receptor Channels Mediate the Release of Cardioprotectants Induced by Ischemic Pre- and Postconditioning

Abstract

Ischemic pre- and postconditioning protect ex vivo rat hearts from ischemia/reperfusion injury by promoting the release of cardioprotective agents by an unknown mechanism. Because P2X₇ purinergic receptors are known to combine with pannexin-1 to form channels that allow adenosine triphosphate (ATP) release from cells, we hypothesized that these channels have a role in the release of multiple cardioprotectants during ischemic preconditioning (IPC). Addition of either a pannexin-1 hemichannel blocker (5 μmol/L carbenoxolone [CBX] or 0.4 μmol/L mefloquine [MF]) or a selective antagonist of the rat P2X₇ purinergic receptor (2 μmol/L brilliant blue G [BBG]) blocked IPC. These antagonists also blocked ischemic postconditioning. Preconditioning by exogenous addition of either sphingosine-1-phosphate or adenosine was not blocked by either CBX or BBG, indicating that they only affected the release of endogenous mediators, not any subsequent steps. To determine if only ATP release was mediated by pannexin-1/P2X₇ channels, we added an extra cycle of IPC to release sufficient quantities of additional cardioprotectants to eliminate the dependence on adenosine derivatives. This did not override the inhibition of IPC by CBX or MF, suggesting that the channel mediates the release of multiple cardioprotectants. Inhibitors of other P2X receptors, P2Y receptors, or connexins did not affect IPC. We conclude that a pannexin-1/P2X₇ channel is responsible for the release of cardioprotectants induced by ischemic pre- and postconditioning.

Keywords

Adenosine brilliant blue G carbenoxolone cardioprotection ischemia reperfusion injury pannexin-1 P2X7 receptor postconditioning preconditioning sphingosine-1-phosphate

References

Jennings RB , Reimer KA The cell biology of acute myocardial ischemia. Annu Revs Med . 1991;42:225-246.

Buja LM , Entman ML Modes of myocardial cell injury and cell death in ischemic heart disease . Circulation. 1998;98(14): 1355-1357.

Hansen PR Myocardial reperfusion injury: experimental evidence and clinical relevance . Eur Heart J. 1995;16(6):734-740.

Maxwell SR , Lip GY Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol. 1997 ;58(2):95-117.

Murry CE , Richard VJ , Reimer KA , Jennings RB Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res. 1990; 66(4):913-931.

Deutsch E. , Berger M. , Kussmaul WG , Hirshfeld JW Jr , Hermann HC , Laskey WK Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical hemodynamic, and metabolic features. Circulation . 1990;82(6): 2044-2051.

Zhao Z. - Q. Vinten-Johansen J. Postconditioning : reduction of reperfusion-induced injury. Cardiovasc Res. 2006;70(2):200-211.

Gross ER , Gross GJ Ischemic preconditioning and myocardial infarction: an update and perspective . Drug Discov Today Dis Mech. 2007;4(3):165-74.

Murphy E. , Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury . Physiol Rev. 2008; 88(2):581-609.

10.

Vessey DA , Li L. , Honbo N. , Karliner JS Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and post-conditioning. Am J Physiol Heart Circ Physiol. 2009;297(4):H1429-H1435.

11.

Hausenloy DJ , Tsang A. , Yellon DM The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med. 2004;15(2):69-75.

12.

Morrison RR , Tan XL , Ledent C. , Mustafa SJ , Hofmann PA Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol. 2007;293(4):H2523-H2529.

13.

Dahl G. , Locovei S.

Pannexin: to gap or not to gap, is that a question?

IUBMB Life. 2006;58(7):409-419.

14.

Iglesias R. , Dahl G. , Spray DC , Scemes E. Pannexin1: the molecular substrate of astrocyte"hemichannels .’’ J Neurosci. 2009; 29(21):7092-7097.

15.

Pelegrin P. , Surprenant A. The P2X7 receptor-pannexin connection to dye uptake and IL-1β release. Purinergic Signal. 2009; 5(2):129-137.

16.

North RA Molecular physiology of P2X receptors. Physiol Rev . 2002;82(4):1013-1067.

17.

Baranova A. , Ivanov D. , Petrash N. , et al. The mammalian pannexin family is homologous to the invertebrate innexin gap junction proteins . Genomics . 2004;83(4):706-716.

18.

Ray A. , Zoidl G. , Weickert S. , Wahle P. , Dermietzel R. Site-specific and developmental expression of pannexin1 in the mouse nervous system. Eur J Neurosci. 2005;21(12):3277-3290.

19.

Musa H. , Tellez JO , Chandler NJ , et al. P2 purinergic receptro mRNA in rat and human sinoatrial node and other heart regions. Naunyn-Schmiedebergs Arch Pharmacol. 2009;379(6):541-549.

20.

Vessey DA , Kelley M. , Li L. , et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit. 2006;12(10):BR318-BR324.

21.

Vessey DA , Li L. , Kelley M. , Karliner JS Sphingosine can pre-and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol . 2008;22(2): 113-118.

22.

Vessey DA , Kelley M. , Li L. , Huang Y. Sphingosine protects aging hearts from ischemia/reperfusion injury. Superiority to sphingosine 1-phosphate and ischemic pre- and post-conditioning . Oxid Med Cell Longev. 2009;2(3):146-151.

23.

Bruzzone R. , Barbe MT , Jakob NJ , Monyer H. Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. J Neurochem. 2005;92(5): 1033-1043.

24.

Ma W. , Hui H. , Pelegrin P. , Surprenant A. Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. J Pharmacol Exp Ther. 2009;328(2):409-418.

25.

Iglesias R. , Locovei S. , Roque A. , et al. P2X7 receptor-pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol. 2008;295(3):C752-C760.

26.

Jiang L. , Mackenzie AB , North RA , Surprenant A. Brilliant blue G selectively blocks ATP-gated rat P2X7 receptors. Mol Pharmacol. 2000;58(1):82-88.

27.

von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther. 2006 ;110(3):415-432.

28.

Evans WH , Leybaert L. Mimetic peptides as blockers of connexin channel-facilitated intercellular communication. Cell Commun Adhes. 2007;14(6):265-273.

29.

van Veen TAB , van Rijen HVM , Opthof T. Cardiac gap junction channels: modulation of expression and channel properties. Cardiovasc Res. 2001;51(2):217-229.

30.

Srinivas M. , Hopperstad MG , Spray DC Quinine blocks specific gap junction channel subtypes. Proc Natl Acad Sci U S A. 2001; 98(19):10942-10947.

31.

Cruikshank SJ , Hopperstad M. , Younger M. , Connors BW , Spray DC Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci U S A. 2004;101(33): 12364-12369.

32.

Thompson RJ , Zhou N. , MacVicar BA Ischemia opens neuronal gap junction hemichannels . Science. 2006 ;312(5775):924-927.

33.

Locovei S. , Scemes E. , Qui F. , Spray DC , Dahl G. Pannexin 1 is part of the pore forming unit of the P2X7 receptor death complex . FEBS Lett. 2007;581(3):483-488.